NCT00331175
Completed
Phase 1
A Phase 1, Randomized, Placebo- And Positive Controlled Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single Escalating Doses Of Intravenous Peptide YY3-36 In Otherwise Healthy Overweight Adult Subjects
ConditionsObesity
DrugsPeptide YY3-36
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Obesity
- Sponsor
- Pfizer
- Enrollment
- 31
- Locations
- 1
- Primary Endpoint
- Food intake
- Status
- Completed
- Last Updated
- 19 years ago
Overview
Brief Summary
The purpose of this trial is to evaluate the safety and tolerability of single escalating doses of Peptide YY3-36 and to determine effects on food intake and serum hormones when administered by intravenous infusion to otherwise healthy overweight adult subjects.
Investigators
Eligibility Criteria
Inclusion Criteria
- •BMI 27-35 kg/m2
Exclusion Criteria
- •Women of childbearing potential
Outcomes
Primary Outcomes
Food intake
Secondary Outcomes
- Plasma biomarkers, safety, toleration
Study Sites (1)
Loading locations...
Similar Trials
Active, not recruiting
Phase 1
Safety, PK/PD, and Immunogenicity Study of SC ALXN2030 in Healthy ParticipantsHealthyNCT05501717Alexion Pharmaceuticals, Inc.48
Completed
Phase 1
A Study to Evaluate ALN-AGT01 RVR in Adult Healthy VolunteersHealthy VolunteersNCT06675565Alnylam Pharmaceuticals42
Completed
Phase 1
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of C16TR for Inhalation With Tyvaso® Cohort in Healthy ParticipantsHealthy VolunteersNCT06193031Insmed Incorporated24
Completed
Phase 1
A Study to Test the Safety, Pharmacokinetics, and Efficacy of UCB9741 in Healthy Study Participants and in Study Participants With Atopic DermatitisAtopic DermatitisNCT04643457UCB Biopharma SRL107
Completed
Phase 1
A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)Atopic DermatitisNCT05277571UCB Biopharma SRL273